Skip Navigation

European Heart Journal 2003 24(2):125-126; doi:10.1016/S0195-668X(02)00628-0
Copyright © 2003 by the European Society of Cardiology.
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Cohn, J.N
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cohn, J.N
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Hotline Editorial

Angiotensin receptor blockers and clinical trials in heart failure

J.N Cohn

University of Minnesota, Minneapolis, MN, USA

The first 10% of the full text of this article appears below.

Growing evidence that angiotensin II contributes to the structural abnormalities of the left ventricle and vasculature that characterize chronic heart failure has made it attractive to study the efficacy of angiotensin AT1-receptor blockade in this syndrome. The problem, however, has been in experimental design. Since most patients should be and are taking ACE inhibitors, and ACE inhibitors are thought to reduce angiotensin II formation, conventional wisdom suggested that angiotensin receptor blockers should be considered as alternatives to ACE inhibitors, not as supplemental therapy.Indeed, the earlier ELITE trial compared the efficacy of the two drug classes with . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Am Coll CardiolHome page
M. Wong, L. Staszewsky, R. Latini, S. Barlera, R. Glazer, N. Aknay, A. Hester, I. Anand, and J. N. Cohn
Severity of left ventricular remodeling defines outcomes and response to therapy in heart failure: Valsartan heart failure trial (Val-HeFT) echocardiographic data
J. Am. Coll. Cardiol., June 2, 2004; 43(11): 2022 - 2027.
[Abstract] [Full Text] [PDF]